FA
SUPN icon

Fortis Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Fortis Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,012
Closed -$162K – 310
2020
Q1 		$162K Buy
+9,012
New +$189K 0.11% 102

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fortis Advisors's SUPN Position: Q2 2020 in Review

Fortis Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 9,012 shares — an estimated $162K sold.

Fortis Advisors first reported a position in SUPN in Q1 2020 and held it in 1 quarter. The position peaked at $162K in Q1 2020. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • Fortis Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Fortis Advisors sold 9,012 Supernus Pharmaceuticals shares in Q2 2020, an estimated $162K.
  • Fortis Advisors first reported a position in Supernus Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Fortis Advisors's Supernus Pharmaceuticals position peaked at $162K in Q1 2020.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Fortis Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.